<DOC>
	<DOCNO>NCT00444613</DOCNO>
	<brief_summary>The purpose study investigate efficacy confirm safety E0302 patient Amyotrophic Lateral Sclerosis ( ALS ) assess change score survival rate functional rating scale .</brief_summary>
	<brief_title>A Study Patients With Amyotrophic Lateral Sclerosis ( ALS )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Vitamin B 12</mesh_term>
	<criteria>1 . Patients able submit write informed consent . If patient duly capable study consent unable sign ( affix seal ) due aggravation disease condition , write informed consent obtain legally authorize representative sign behalf patient confirm patient ' agreement study participation . 2 . Patients age 20 year old time obtain informed consent . 3 . Patients clinically definite ALS , clinically probable ALS , clinically probablelaboratory support ALS specify revise El Escorial Airlie House diagnostic criterion . 4 . Patients stage 1 2 severity criterion ALS . 5 . Patients within 3year elapsed time period disease onset start observation period . 6 . Patients visit study site outpatient treatment . 1 . Patients underwent tracheostomy . 2 . Patients experience noninvasive positive pressure ventilation . 3 . Patients whose percentpredicted force vital capacity ( % FVC ) &gt; =60 % . 4 . Patients multiple disturbance conduction detect nerve conduction test . 5 . Patients neurological symptom ( ) due vitamin B12 deficiency . 6 . Patients initiated newly introduce riluzole therapy start observation period . Or receive dose escalation resume administration riluzole therapy previous titration discontinuation . 7 . Patients cognitive impairment . 8 . Pregnant woman woman possibility become pregnant . 9 . Patients partner willing use reliable contraception . 10 . Patients severe disease renal , cardiovascular , hematological , hepatic system ( severe disease judge refer `` Ministry Health , Labor Welfare '' ( MHLW ) Drug Safety Dept . Notification No . 80 , Drug Safety Classification Criteria Severity Adverse Drug Reaction Medicinal Products , Grade 3 ) . 11 . Patients malignant tumor . 12 . Patients participate another clinical study within 12 week start observation period . 13 . Patients present illness history drug allergy severe allergic disease ( anaphylactic shock ) . 14 . Patients judge ineligible study entry investigator subinvestigator .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Amyotrophic Lateral Sclerosis ( ALS )</keyword>
	<keyword>motor neuron</keyword>
	<keyword>muscular atrophy</keyword>
	<keyword>Lou Gehrig 's Disease</keyword>
</DOC>